Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$17.00 -1.1%	$18.42	$13.50 ▼ $25.67	$4.06B	0.38	3.15 million shs	1.71 million shs
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
CRSP CRISPR Therapeutics	$58.89 +2.7%	$52.73	$30.04 ▼ $71.13	$5.36B	1.8	2.62 million shs	4.28 million shs
PCVX Vaxcyte	$31.45 -0.3%	$34.18	$27.66 ▼ $121.06	$4.08B	1.21	1.79 million shs	857,268 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	+2.63%	-7.23%	-7.92%	-10.42%	-0.41%
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	+1.91%
CRSP CRISPR Therapeutics	+2.24%	+2.71%	+2.56%	+59.37%	+20.00%
PCVX Vaxcyte	+5.17%	-4.39%	-13.28%	+2.10%	-59.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMA ADMA Biologics	4.2882 of 5 stars	3.7	3.0	0.0	0.0	3.2	2.5	3.1
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	3.1687 of 5 stars	3.3	3.0	0.0	0.0	3.2	3.3	0.6
PCVX Vaxcyte	2.042 of 5 stars	3.5	2.0	0.0	0.0	2.3	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	3.33	Buy	$27.67	62.71% Upside
CALT Calliditas Therapeutics AB (publ)	0.00	N/A	N/A	N/A
CRSP CRISPR Therapeutics	2.50	Moderate Buy	$71.60	21.59% Upside
PCVX Vaxcyte	3.09	Buy	$136.50	334.08% Upside

Current Analyst Ratings Breakdown

Latest CALT, CRSP, ADMA, and PCVX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	PCVX Vaxcyte	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/7/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$65.00 ➝ $80.00
8/6/2025	CRSP CRISPR Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$42.00 ➝ $56.00
8/5/2025	CRSP CRISPR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$82.00
8/5/2025	CRSP CRISPR Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$38.00 ➝ $42.00
7/22/2025	CRSP CRISPR Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$79.00 ➝ $78.00
7/8/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
6/27/2025	CRSP CRISPR Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$105.00
6/27/2025	CRSP CRISPR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$86.00
6/27/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$65.00
6/26/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$426.45M	9.52	$0.55 per share	30.97	$1.67 per share	10.18
CALT Calliditas Therapeutics AB (publ)	$1.60B	0.74	N/A	N/A	$1.06 per share	37.74
CRSP CRISPR Therapeutics	$37.31M	143.55	N/A	N/A	$18.81 per share	3.13
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$23.66 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$197.67M	$0.86	19.77	24.64	N/A	44.06%	41.01%	28.47%	N/A
CALT Calliditas Therapeutics AB (publ)	-$43.96M	-$1.85	N/A	8.68	N/A	-30.18%	-212.04%	-27.96%	N/A
CRSP CRISPR Therapeutics	-$366.25M	-$5.43	N/A	N/A	N/A	-1,229.43%	-20.05%	-17.09%	N/A
PCVX Vaxcyte	-$463.93M	-$4.11	N/A	N/A	N/A	N/A	-16.85%	-15.92%	N/A

Latest CALT, CRSP, ADMA, and PCVX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	ADMA ADMA Biologics	$0.14	$0.15	+$0.01	$0.14	$121.77 million	$121.98 million
8/6/2025	Q2 2025	PCVX Vaxcyte	-$1.12	-$1.22	-$0.10	-$1.22	N/A	N/A
8/4/2025	Q2 2025	CRSP CRISPR Therapeutics	-$1.47	-$1.29	+$0.18	-$2.40	$6.44 million	$0.89 million
5/14/2025	Q1 2025	PCVX Vaxcyte	-$1.02	-$1.04	-$0.02	-$1.04	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.21	5.33	2.78
CALT Calliditas Therapeutics AB (publ)	9.44	2.69	2.59
CRSP CRISPR Therapeutics	N/A	16.61	16.61
PCVX Vaxcyte	N/A	11.11	11.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
CALT Calliditas Therapeutics AB (publ)	2.83%
CRSP CRISPR Therapeutics	69.20%
PCVX Vaxcyte	96.78%

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.50%
CALT Calliditas Therapeutics AB (publ)	2.20%
CRSP CRISPR Therapeutics	4.30%
PCVX Vaxcyte	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	530	238.73 million	230.38 million	Optionable
CALT Calliditas Therapeutics AB (publ)	180	29.79 million	29.14 million	Optionable
CRSP CRISPR Therapeutics	460	90.95 million	87.04 million	Optionable
PCVX Vaxcyte	160	129.82 million	125.80 million	Optionable

CALT, CRSP, ADMA, and PCVX Headlines

Recent News About These Companies

Caitong International Asset Management Co. Ltd Raises Position in Vaxcyte, Inc. (NASDAQ:PCVX)

August 14 at 7:01 AM | marketbeat.com

Citigroup Inc. Has $23.45 Million Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

August 14 at 4:23 AM | marketbeat.com

Deutsche Bank AG Trims Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

August 13 at 3:45 AM | marketbeat.com

Vaxcyte FY2025 EPS Estimate Reduced by Cantor Fitzgerald

August 12 at 2:49 AM | americanbankingnews.com

Leerink Partnrs Brokers Lower Earnings Estimates for Vaxcyte

August 12 at 2:47 AM | americanbankingnews.com

Cantor Fitzgerald Reduces Earnings Estimates for Vaxcyte

August 11 at 2:50 AM | marketbeat.com

Leerink Partnrs Has Bearish Estimate for Vaxcyte Q3 Earnings

August 11 at 2:43 AM | marketbeat.com

Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Headlands Technologies LLC

August 9, 2025 | marketbeat.com

Vaxcyte (NASDAQ:PCVX) Shares Gap Down Following Weak Earnings

August 8, 2025 | marketbeat.com

Vaxcyte (NASDAQ:PCVX) Shares Gap Down on Disappointing Earnings

August 8, 2025 | americanbankingnews.com

Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class ...

August 7, 2025 | finance.yahoo.com

Vaxcyte price target lowered to $50 from $85 at TD Cowen

August 7, 2025 | msn.com

XTX Topco Ltd Boosts Stake in Vaxcyte, Inc. (NASDAQ:PCVX)

August 7, 2025 | marketbeat.com

Vaxcyte (PCVX) Q2 Loss Widens 11%

August 6, 2025 | fool.com

Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)

August 6, 2025 | globenewswire.com

J. Safra Sarasin Holding AG Acquires New Stake in Vaxcyte, Inc. (NASDAQ:PCVX)

August 5, 2025 | marketbeat.com

Westfield Capital Management Co. LP Has $81.38 Million Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

August 4, 2025 | marketbeat.com

Assetmark Inc. Acquires 13,648 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

August 3, 2025 | marketbeat.com

Vaxcyte, Inc. (PCVX)’s VAX-24 Achieves Phase 2 Success in Infants

July 31, 2025 | finance.yahoo.com

Vaxcyte, Inc. (PCVX)’s VAX-24 Achieves Phase 2 Success in Infants

July 31, 2025 | insidermonkey.com

Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by TD Asset Management Inc

July 31, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALT, CRSP, ADMA, and PCVX Company Descriptions

ADMA Biologics NASDAQ:ADMA

$17.00 -0.20 (-1.14%)

Closing price 03:59 PM Eastern

Extended Trading

$16.96 -0.04 (-0.23%)

As of 04:10 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)

As of 08/12/2025

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

CRISPR Therapeutics NASDAQ:CRSP

$58.89 +1.56 (+2.72%)

Closing price 03:59 PM Eastern

Extended Trading

$58.50 -0.39 (-0.66%)

As of 04:10 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Vaxcyte NASDAQ:PCVX

$31.45 -0.10 (-0.33%)

Closing price 03:59 PM Eastern

Extended Trading

$31.42 -0.02 (-0.07%)

As of 04:10 PM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time